Inmune Bio Stock Probability of Future Stock Price Finishing Under 4.8
| INMB Stock | USD 5.05 0.16 3.27% |
INmune |
INmune Bio Target Price Odds to finish below 4.8
The tendency of INmune Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 4.80 or more in 90 days |
| 5.05 | 90 days | 4.80 | about 10.58 |
Based on a normal probability distribution, the odds of INmune Bio to drop to $ 4.80 or more in 90 days from now is about 10.58 (This INmune Bio probability density function shows the probability of INmune Stock to fall within a particular range of prices over 90 days) . Probability of INmune Bio price to stay between $ 4.80 and its current price of $5.05 at the end of the 90-day period is about 10.34 .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.16 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, INmune Bio will likely underperform. Additionally INmune Bio has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. INmune Bio Price Density |
| Price |
Predictive Modules for INmune Bio
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as INmune Bio. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.INmune Bio Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. INmune Bio is not an exception. The market had few large corrections towards the INmune Bio's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold INmune Bio, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of INmune Bio within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.65 | |
β | Beta against Dow Jones | 2.16 | |
σ | Overall volatility | 0.57 | |
Ir | Information ratio | -0.12 |
INmune Bio Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of INmune Bio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for INmune Bio can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| INmune Bio generated a negative expected return over the last 90 days | |
| INmune Bio has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 155 K. Net Loss for the year was (30.01 M) with profit before overhead, payroll, taxes, and interest of 374 K. | |
| INmune Bio currently holds about 61.21 M in cash with (11.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.41. | |
| INmune Bio has a frail financial position based on the latest SEC disclosures | |
| Roughly 29.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Scotiabank Initiates Coverage of INmune Bio with Sector Outperform Recommendation - MSN |
INmune Bio Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of INmune Stock often depends not only on the future outlook of the current and potential INmune Bio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. INmune Bio's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 18 M | |
| Cash And Short Term Investments | 35.8 M |
INmune Bio Technical Analysis
INmune Bio's future price can be derived by breaking down and analyzing its technical indicators over time. INmune Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of INmune Bio. In general, you should focus on analyzing INmune Stock price patterns and their correlations with different microeconomic environments and drivers.
INmune Bio Predictive Forecast Models
INmune Bio's time-series forecasting models is one of many INmune Bio's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary INmune Bio's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about INmune Bio
Checking the ongoing alerts about INmune Bio for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for INmune Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| INmune Bio generated a negative expected return over the last 90 days | |
| INmune Bio has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 155 K. Net Loss for the year was (30.01 M) with profit before overhead, payroll, taxes, and interest of 374 K. | |
| INmune Bio currently holds about 61.21 M in cash with (11.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.41. | |
| INmune Bio has a frail financial position based on the latest SEC disclosures | |
| Roughly 29.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Scotiabank Initiates Coverage of INmune Bio with Sector Outperform Recommendation - MSN |
Check out INmune Bio Backtesting, INmune Bio Valuation, INmune Bio Correlation, INmune Bio Hype Analysis, INmune Bio Volatility, INmune Bio History as well as INmune Bio Performance. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.18) | Revenue Per Share 0.002 | Quarterly Revenue Growth (0.63) | Return On Assets (0.45) | Return On Equity (0.99) |
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.